Skip to main content
Clinical Trials/NCT01514435
NCT01514435
Completed
Not Applicable

Clinical Effects of Electroconvulsive Therapy in Severe Depression and Concomitant Changes in Cerebral Glucose Metabolism - an Exploratory Study

Medical University of Graz1 site in 1 country13 target enrollmentMay 2006

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Major Depressive Disorder
Sponsor
Medical University of Graz
Enrollment
13
Locations
1
Primary Endpoint
Brain glucose metabolism measured by FDG-PET
Status
Completed
Last Updated
14 years ago

Overview

Brief Summary

There exist already a few studies that have measured changes of brain metabolism pre and post Electroconvulsive Therapy (ECT) by Positron emission tomography (PET) but these were all performed in a small number of patients and used different methodologies. It is therefore not surprising that these investigations provided inconsistent results, as reviewed previously {{23 Schmidt,E.Z. 2008}}.

In patients with treatment-refractory major depressive episodes, the investigators here therefore probed (a) whether changes in cerebral glucose metabolism measured by PET occur after treatment with ECT and (b) whether these correlate with the clinical amelioration of symptoms. To pursue this goal, the investigators assessed clinical effects, neurocognitive function, and brain metabolism using 18F-Fluoro-deoxyglucose (18F-FDG) PET at baseline and at the end of treatment.

Patients with a treatment refractory depression - defined as absent clinical improvement of depressive symptoms after at least two trials with antidepressants from different pharmacologic classes adequate in dose, duration of at least 6 weeks, and compliance {{30 Berlim,M.T. 2007}} - in whom ECT had been intended on clinical grounds were consecutively asked for participation in this study. Patients had to be between 18 and 80 years old and to be physically healthy.

Registry
clinicaltrials.gov
Start Date
May 2006
End Date
July 2011
Last Updated
14 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Medical University of Graz
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • clinical indication for ECT
  • treatment refractory depressive episode
  • age 18-85 y

Exclusion Criteria

  • addiction as a first diagnosis

Outcomes

Primary Outcomes

Brain glucose metabolism measured by FDG-PET

Time Frame: one year

Study Sites (1)

Loading locations...

Similar Trials